EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSPNYG00000008908
Gene Symbol: KCNK2
4 Cross references
213 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSPNYG00000023221
Gene Symbol: KCNK3
3 Cross references
200 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSPNYG00000010882
Gene Symbol: KCNK9
3 Cross references
218 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSPNYG00000022842
Gene Symbol: KCNA5
2 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSPNYG00000014453
Gene Symbol: KCND3
3 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSPNYG00000013042
Gene Symbol: KCND3
4 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSPNYG00000020864
Gene Symbol: KCNH2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSPNYG00000013306
Gene Symbol: LOC102199450
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSPNYG00000014711
Gene Symbol: KCNQ2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSPNYG00000016289
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSPNYG00000009016
Gene Symbol: KCNQ5
3 Cross references
196 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSPNYG00000015979
Gene Symbol: PSEN2
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).